MRK vs. MTD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at MRK and MTD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | MRK | MTD |
|---|---|---|
| Company Name | Merck & Co., Inc. | Mettler-Toledo International Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 215.32 billion USD | 29.27 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 1962 | November 14, 1997 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of MRK and MTD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | MRK | MTD |
|---|---|---|
| 5-Day Price Return | 3.45% | 0.86% |
| 13-Week Price Return | 8.40% | 14.01% |
| 26-Week Price Return | 9.64% | 32.10% |
| 52-Week Price Return | -14.25% | 1.49% |
| Month-to-Date Return | 0.90% | 1.15% |
| Year-to-Date Return | -12.80% | 17.07% |
| 10-Day Avg. Volume | 11.26M | 0.16M |
| 3-Month Avg. Volume | 12.01M | 0.15M |
| 3-Month Volatility | 28.25% | 28.42% |
| Beta | 0.32 | 1.42 |
Profitability
Return on Equity (TTM)
MRK
38.95%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
MRK’s Return on Equity of 38.95% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
MTD
1,675.84%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
MTD’s Return on Equity of 1,675.84% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
MRK
29.63%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 29.63% places MRK in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
MTD
21.20%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
A Net Profit Margin of 21.20% places MTD in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
MRK
33.73%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
An Operating Profit Margin of 33.73% places MRK in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
MTD
26.24%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
An Operating Profit Margin of 26.24% places MTD in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | MRK | MTD |
|---|---|---|
| Return on Equity (TTM) | 38.95% | 1,675.84% |
| Return on Assets (TTM) | 15.88% | 24.95% |
| Net Profit Margin (TTM) | 29.63% | 21.20% |
| Operating Profit Margin (TTM) | 33.73% | 26.24% |
| Gross Profit Margin (TTM) | 78.72% | 59.73% |
Financial Strength
Current Ratio (MRQ)
MRK
1.66
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
MRK’s Current Ratio of 1.66 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
MTD
1.07
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
MTD’s Current Ratio of 1.07 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
MRK
0.80
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
MRK’s Debt-to-Equity Ratio of 0.80 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MTD
81.23
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
With a Debt-to-Equity Ratio of 81.23, MTD operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
MRK
19.65
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
MRK’s Interest Coverage Ratio of 19.65 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
MTD
15.60
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
MTD’s Interest Coverage Ratio of 15.60 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | MRK | MTD |
|---|---|---|
| Current Ratio (MRQ) | 1.66 | 1.07 |
| Quick Ratio (MRQ) | 1.44 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 0.80 | 81.23 |
| Interest Coverage Ratio (TTM) | 19.65 | 15.60 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
MRK
3.79%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 3.79%, MRK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
MTD
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
MTD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
MRK
42.60%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
MRK’s Dividend Payout Ratio of 42.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
MTD
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
MTD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | MRK | MTD |
|---|---|---|
| Dividend Yield (TTM) | 3.79% | 0.00% |
| Dividend Payout Ratio (TTM) | 42.60% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
MRK
11.25
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
In the lower quartile for the Pharmaceuticals industry, MRK’s P/E Ratio of 11.25 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
MTD
35.14
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
MTD’s P/E Ratio of 35.14 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
MRK
3.33
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
MRK’s P/S Ratio of 3.33 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
MTD
7.45
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
MTD’s P/S Ratio of 7.45 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
MRK
4.04
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
MRK’s P/B Ratio of 4.04 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MTD
1,299.40
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
At 1,299.40, MTD’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | MRK | MTD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 11.25 | 35.14 |
| Price-to-Sales Ratio (TTM) | 3.33 | 7.45 |
| Price-to-Book Ratio (MRQ) | 4.04 | 1,299.40 |
| Price-to-Free Cash Flow Ratio (TTM) | 16.41 | 33.01 |